This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.
Drug: Remdesivir
Remdesivir 100 IV Infusion as a lyophilized powder
Drug: Tocilizumab
Actemra IV Infusion
Other Name: Actemra IV Infusion
Inclusion Criteria:
Severe COVID-19 patients require hospitalization under HDU/ICU. The SARS-CoV-2 infection
will be confirmed by RT PCR / CT Chest in every case.
Exclusion Criteria:
- Participants with uncontrolled clinical status who were hospitalized from the before.
- Contraindication / possible drug interaction.
- Participants who have any severe and/or uncontrolled medical conditions like, Severe
ischemic heart disease, epilepsy, malignancy, Pulmonary/renal/hepatic disease, AIDS,
Pulmonary TB, pregnancy, Corpulmonale, and etc.
Chattogram General Hospital
Chittagong, Bangladesh
Cox's Bazar 250 Bed District Sadar Hospital
Cox's Bazar, Bangladesh
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh